The Effect of Stellate Ganglion Block on Breast Cancer-Related Infectious Lymphedema.
10.14475/kjhpc.2018.21.4.158
- Author:
Youn Young LEE
1
;
Hahck Soo PARK
;
Yeon Sil LEE
;
Seung Hee YOO
;
Heeseung LEE
;
Won Joong KIM
Author Information
1. Department of Anesthesiology and Pain Medicine, Ewha Womans University College of Medicine, Seoul, Korea. ingoo97@naver.com
- Publication Type:Case Report
- Keywords:
Lymphedema;
Stellate ganglion;
Breast neoplasms;
Breast cancer lymphedema
- MeSH:
Arm;
Breast Neoplasms;
Breast*;
Cellulitis;
Depression;
Elbow;
Humans;
Lymphedema*;
Pain Clinics;
Quality of Life;
Range of Motion, Articular;
Risk Factors;
Shoulder;
Stellate Ganglion*
- From:Korean Journal of Hospice and Palliative Care
2018;21(4):158-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
Breast cancer related lymphedema (BCRL) is one of the most intractable complications after surgery. Patients suffer from physical impairment, as well as psychological depression. Moreover, a recent study revealed that cellulitis significantly increased the risk of BCRL, and cellulitis has been suggested as a risk factor of BCRL development. We describe a patient treated with stellate ganglion blocks (SGBs) without steroid for relief of symptoms and reduction of the arm circumference of breast cancer-related infectious lymphedema in a month. We measured the arm circumference at four locations; 10 cm and 5 cm above and below the elbow crease, numeric rating scale (NRS) score, lymphedema and breast cancer questionnaire (LBCQ) score on every visit to the pain clinic. A serial decrease of the arm circumference and pain score were observed after second injection. In the middle of the process, cellulitis recurred, we performed successive SGBs to treat infectious lymphedema. The patient was satisfied with the relieved pain and swelling, especially with improved shoulder range of motion as it contributes to better quality of life. This case describes the effects of SGB for infectious BCRL patients. SGB could be an alternative or ancillary treatment for infectious BCRL patients.
